How AI Is Changing the Prior Authorization Landscape: For Patients and Providers
How AI Is Changing the Prior Authorization Landscape: For Patients and Providers
Audience: Physicians, PA coordinators, nurse navigators
Published: 2026-04-01
Category: Industry Trends, Prior Authorization
How AI Is Changing the Prior Authorization Landscape: For Patients and Providers
6 minute read
Artificial intelligence is being deployed in prior authorization at scale. The deployment is not evenly distributed. In the current landscape, insurers have adopted AI-driven claim review at a rate that significantly outpaces the adoption of AI tools on the provider and patient side. Understanding what is happening, and what the clinical and administrative implications are, matters for any practice managing a meaningful volume of prior authorization requests.
How Insurers Are Using AI in Prior Authorization
The most significant and documented application of AI in prior authorization is automated denial. Several major insurers have deployed algorithmic review systems that generate prior authorization denials without direct physician review of individual cases. The mechanics vary by insurer and program, but the common architecture involves:
Algorithmic screening at submission. When a prior authorization request is submitted, AI systems scan the documentation against coverage criteria and generate a preliminary decision. Requests that meet all criteria on the initial scan may be approved automatically. Requests that fail any criteria flag for denial.
Volume-based denial at speed. The algorithmic systems operate at a scale and speed that human reviewers cannot match. A 2023 investigation by ProPublica and The Capitol Forum documented that UnitedHealth Group's AI-driven denial system reviewed claims at a rate that implied an average of approximately 1.2 seconds per claim, with a denial rate for certain claim types that was substantially higher than industry averages.¹
Physician reviewer confirmation. In at least some systems, human medical directors reviewing AI-flagged denials have described having limited time per case, confirming algorithmic decisions rather than independently reviewing clinical documentation. A 2023 lawsuit against UnitedHealth Group alleged that its AI model, nAVIgator, denied claims that contradicted individual patient clinical data.¹
CMS attention. The Centers for Medicare and Medicaid Services has taken note. A 2022 CMS audit of Medicare Advantage prior authorization found that 13 percent of denied prior authorization requests met Medicare coverage criteria and should have been approved.² CMS issued a rule in 2024 tightening prior authorization standards for Medicare Advantage plans, including requirements around AI-generated denials.
What This Means for Provider Submissions
The implications of AI-driven denial systems for provider PA submissions are direct.
The initial submission is more important than it used to be. When a human reviewer reads an LMN, they can interpret context, ask follow-up questions, and exercise clinical judgment. An algorithmic system scans for the presence or absence of specific documentation elements. A letter that is clinically strong but does not explicitly state the required criteria in the expected format may generate an algorithmic denial that a human reviewer would have approved.
This means the technical structure of a prior authorization letter, how it is formatted, which criteria it addresses explicitly, in what sequence, has become more important than it was when human reviewers were reading every submission.
Payer-specific language matters more. Algorithmic review systems are calibrated to the payer's own coverage criteria language. Letters that use the payer's specific terminology for clinical criteria are more likely to pass algorithmic screening than letters that describe the same clinical situation in non-payer-specific language.
Completeness checking is now a submission standard. An incomplete PA submission that a human reviewer might have followed up on is more likely to generate an automatic denial from an algorithmic system. The letter must be complete at submission: diagnosis documentation, prior treatment history, lab values where required, clinical rationale, and payer-specific criteria addressed. There is no second chance at first submission.
What This Means for the Appeal Process
AI-driven denial systems have also changed the appeal calculus.
Denial rates are up, particularly for certain drug classes. The AHIP (America's Health Insurance Plans) 2023 data shows that prior authorization denial rates vary substantially by insurer and drug class, with some payers posting denial rates for certain biologics that exceed 20 percent of initial submissions.³ Higher denial rates mean more appeal volume.
The appeal must address the algorithmic reason, not just the clinical reason. When a denial comes from an algorithmic system, the stated denial reason is often a criteria checklist item: "insufficient documentation of prior therapy," "diagnosis not supported by submitted documentation," "quantity exceeds coverage limit." An effective appeal addresses that specific item explicitly, with the specific evidence that counters it.
Generic appeal letters, the ones that reassert medical necessity without addressing the stated denial reason, fail against algorithmic review just as they fail against human review. The only difference is that algorithmic systems may deny faster, and with less opportunity to negotiate informally.
External review is underused. When a prior authorization appeal is denied after internal review, patients have the right to external independent review in all states. External reviewers are independent of the insurer, and external review overturn rates are meaningful: a 2022 KFF analysis found that external reviewers overturned insurer denials in approximately 37 to 62 percent of cases, depending on the state.⁴ Providers and nurse navigators should be routinely counseling patients about external review as an available option after internal appeal exhaustion.
What AI Looks Like on the Provider and Patient Side
The asymmetry in AI adoption between insurers and providers has been a recurring theme in congressional testimony and medical society advocacy. The argument is straightforward: if insurers can use AI to generate denials at scale, providers and patients should have access to AI tools that help them respond at comparable scale.
That argument is beginning to produce tools.
On the provider side, tools that incorporate payer-specific coverage criteria and generate letters structured to meet those criteria are addressing the single highest-leverage point in the PA process. The submission quality problem, building a first submission that passes algorithmic review, is more tractable than the appeals problem.
On the patient side, tools that help patients understand denial letters in plain language, prepare their own appeal submissions as covered persons, and document their clinical history are expanding the channel through which authorization decisions can be contested.
The value of parallel action, providers and patients both engaging the appeal process simultaneously, is increasingly well-documented. Payers are more likely to reverse a denial when both the prescribing physician and the covered member have submitted appeals, because reversal becomes the path of least resistance administratively.
What Practices Should Track
The AI-in-PA landscape is changing quickly. A few things worth tracking at the practice level:
CMS Medicare Advantage prior authorization regulations are evolving. The 2024 rule and its implementation guidance are relevant for any practice with a significant Medicare Advantage population.
State prior authorization reform laws are passing at an increasing rate. Gold carding requirements, AI-denial transparency mandates, and prior authorization reform bills have been enacted in a growing number of states and affect how payers operating in those states can use algorithmic review.
Insurer-specific denial rate trends. Practices with high PA volume should track denial rates by payer and drug class. Significant increases in denial rates from a specific payer often correlate with a policy change or a new algorithmic screening deployment, and knowing that early allows the practice to adjust submission strategy.
Ellen's payer intelligence database includes policy documentation across 61 insurers, including coverage criteria updates. For providers navigating the current PA environment, starting with the payer's current published criteria before drafting the initial submission remains the highest-leverage step available. Learn more at ellenrx.com/providers.
Sources: